Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atra + toripalimab
- Development stage
- Preclinical
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ATRA + toripalimab is an investigational combination therapy consisting of all-trans retinoic acid (ATRA), a small molecule differentiation agent, and toripalimab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. ATRA promotes differentiation of malignant cells, particularly in acute promyelocytic leukemia, while toripalimab acts as an immune checkpoint inhibitor by blocking PD-1 on T cells to enhance antitumor immune responses. This combination is being explored for synergistic effects in cancer immunotherapy, leveraging ATRA's ability to modulate the tumor microenvironment and increase tumor immunogenicity alongside the immune activation provided by PD-1 blockade.
- Other names
- all-trans retinoic acid + toripalimabatra plus toripalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)RARA (Retinoic acid receptor alpha)
Beyond the preview
Go deeper on atra + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atra + toripalimab.